Alcobra Announces Shares Uplisted to NASDAQ Global Market
26 mars 2014 08h00 HE
|
Alcobra Ltd.
TEL AVIV, Israel, March 26, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary...
Alcobra Announces Enrollment of First Patient in Phase 3 Clinical Trial for MDX in Adult ADHD
18 mars 2014 08h00 HE
|
Alcobra Ltd.
TEL AVIV, Israel, March 18, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary...
Alcobra Announces FDA Clearance of IND for Metadoxine Extended Release (MDX)
06 mars 2014 09h15 HE
|
Alcobra Ltd.
TEL AVIV, Israel, March 6, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
Alcobra Ltd. to Discuss Biomarkers in Fragile X and Autism Trials at the Second Annual Autism Investment Conference
24 févr. 2014 08h00 HE
|
Alcobra Ltd.
TEL AVIV, Israel, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
Alcobra Appoints J.P. Morgan Banker Dr. Tomer Berkovitz as Chief Financial Officer
19 févr. 2014 08h00 HE
|
Alcobra Ltd.
TEL AVIV, Israel, Feb. 19, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
Alcobra Announces Fourth Quarter and Fiscal Year End 2013 Financial Results and Corporate Update
13 févr. 2014 08h00 HE
|
Alcobra Ltd.
TEL AVIV, Israel, Feb. 13, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
Alcobra Announces IND Submission for Extended Release Metadoxine to Treat Adults With ADHD
07 févr. 2014 13h58 HE
|
Alcobra Ltd.
TEL AVIV, Israel, Feb. 7, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
Alcobra Ltd. to Provide Corporate Overview at 16th Annual BIO CEO & Investor Conference
31 janv. 2014 08h00 HE
|
Alcobra Ltd.
TEL AVIV, Israel, Jan. 31, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
Alcobra Ltd. to Release Fourth Quarter 2013 Results and Host Investor Conference Call on Thursday, February 13, 2014
29 janv. 2014 08h00 HE
|
Alcobra Ltd.
TEL AVIV, Israel, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
Alcobra Announces New Biomarker Finding in a Follow-Up Fragile X Animal Study for MG01CI
27 janv. 2014 08h00 HE
|
Alcobra Ltd.
- Improved Cognitive Function and Social Interaction Correlated With Changes in Blood Levels of Fragile X-Specific Molecular Targets
- Clinical Study With MG01CI in Fragile X Syndrome...